NovMetaPharma Co., Ltd. (XKON:229500)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,550
+240 (1.68%)
At close: Aug 1, 2025, 3:30 PM KST
1.68%
Market Cap176.43B
Revenue (ttm)1.30B
Net Income (ttm)408.03M
Shares Out12.13M
EPS (ttm)120.00
PE Ratio121.25
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,699
Average Volume7,626
Open13,500
Previous Close14,310
Day's Range13,500 - 14,960
52-Week Range4,505 - 17,890
Beta0.31
RSI62.16
Earnings Daten/a

About Hess Corporation

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 229500
Full Company Profile

Financial Performance

Financial numbers in BGN Financial Statements

News

There is no news available yet.